[Clostridum difficile associated disease in Latin America].
Clostridium difficile associated disease (CDAD) has shown a sustained increase worldwide over the last ten years. However, there are few studies on this topic in Latin America. We conducted a comprehensive literature review using medical databases of Latin American countries. We found only seven recent papers in which clinical characteristics and risk factors were analyzed; some included outcome variables. Of these articles, only one was prospective, while the rest were either retrospective, cross-sectional or case-control studies. Most studies were done among hospitalized adult patients, even though patients 13+ years were also included in some reports. Only two recent clinical studies used cell culture to determine a cytopathic effect and the rest included immunoenzymatic assays. In general, all the studies we reviewed showed that the use of fluorquinolones, clindamycin, and cephalosporins were the antibiotics mostly associated with CDAD. Treatment schedules generally included metronidazol, although vancomycin was reported in one. Attributable mortality was lower than the mortality described in previous reports from hospitals in developed countries. Studies where this outcome was included did not surpass 4%, a significant difference from the findings from developed countries. In Latin America there are few studies that describe this clinical problem, they generally include small sample sizes and most are retrospective. There is a clear need to design and carry out prospective studies that will allow us to determine the true prevalence of this health problem
Camacho-Ortiz
Adrián
A
Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México D.F., México.
Ponce-de-León
Alfredo
A
Sifuentes-Osornio
José
J
D004761:Enterocolitis, Pseudomembranous / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007843:Latin America